- Home
- NRC vs ALMS Comparison
NRC vs ALMS Comparison
Compare NRC & ALMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRC
- ALMS
- Stock Information
- Founded
- NRC 1981
- ALMS 2021
- Country
- NRC United States
- ALMS United States
- Employees
- NRC N/A
- ALMS N/A
- Industry
- NRC Biotechnology: Commercial Physical & Biological Resarch
- ALMS
- Sector
- NRC Health Care
- ALMS
- Exchange
- NRC Nasdaq
- ALMS NYSE
- Market Cap
- NRC 394.2M
- ALMS 402.6M
- IPO Year
- NRC N/A
- ALMS 2024
- Fundamental
- Price
- NRC $14.04
- ALMS $5.61
- Analyst Decision
- NRC
- ALMS Strong Buy
- Analyst Count
- NRC 0
- ALMS 7
- Target Price
- NRC N/A
- ALMS $26.83
- AVG Volume (30 Days)
- NRC 101.8K
- ALMS 474.1K
- Earning Date
- NRC 04-28-2025
- ALMS 05-14-2025
- Dividend Yield
- NRC 3.44%
- ALMS N/A
- EPS Growth
- NRC N/A
- ALMS N/A
- EPS
- NRC 1.02
- ALMS N/A
- Revenue
- NRC $141,298,000.00
- ALMS $17,389,000.00
- Revenue This Year
- NRC N/A
- ALMS N/A
- Revenue Next Year
- NRC N/A
- ALMS N/A
- P/E Ratio
- NRC $13.71
- ALMS N/A
- Revenue Growth
- NRC N/A
- ALMS N/A
- 52 Week Low
- NRC $9.76
- ALMS $3.18
- 52 Week High
- NRC $35.81
- ALMS $13.53
- Technical
- Relative Strength Index (RSI)
- NRC 63.42
- ALMS N/A
- Support Level
- NRC $13.28
- ALMS N/A
- Resistance Level
- NRC $14.11
- ALMS N/A
- Average True Range (ATR)
- NRC 0.71
- ALMS 0.00
- MACD
- NRC 0.28
- ALMS 0.00
- Stochastic Oscillator
- NRC 95.38
- ALMS 0.00
About NRC National Research Corporation (Delaware)
National Research Corp is a provider of analytics and insights that facilitate measurement and improvement of the patient and employee experience while also increasing patient engagement and customer loyalty for healthcare providers, payers, and other healthcare organizations. Its portfolio of solutions represents a set of capabilities that individually and collectively provide value to clients. It operates in the United States and Canada, of which key revenue is derived from the United States.
About ALMS ALUMIS INC
Alumis Inc is a clinical-stage biopharmaceutical company focused on identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. The Company leverages its proprietary precision data analytics platform, biological insights, and a team of experts with deep experience in precision medicine drug discovery, development, and immunology, to create medicines that significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Company pipeline includes: ESK-001, TYK2, A-OO5, IRF5.